20571-15-7 Usage
Description
Spiro[2.3]hexan-4-one, also known as 4-methyl-1-cyclohexanone or 4-methylcyclohexan-1-one, is a chemical compound with a spirocyclic structure, featuring two rings that share a single common atom. As a cyclic ketone, it contains a carbonyl group within its ring structure.
Uses
Used in Organic Synthesis:
Spiro[2.3]hexan-4-one is used as a building block in organic synthesis for the production of various pharmaceuticals, agrochemicals, and other fine chemicals. Its unique spirocyclic structure and carbonyl group make it a valuable component in the synthesis of complex organic molecules.
Used in Flavor and Fragrance Industry:
In the flavor and fragrance industry, Spiro[2.3]hexan-4-one is used as a scent component in various products. Its distinct aroma profile contributes to the overall scent of perfumes, colognes, and other fragranced products.
Used in Medicinal Applications:
Spiro[2.3]hexan-4-one is of interest for potential medicinal uses due to its anti-inflammatory and anti-fungal properties. It may be employed as an active ingredient in pharmaceutical formulations targeting inflammation and fungal infections.
Check Digit Verification of cas no
The CAS Registry Mumber 20571-15-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,0,5,7 and 1 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 20571-15:
(7*2)+(6*0)+(5*5)+(4*7)+(3*1)+(2*1)+(1*5)=77
77 % 10 = 7
So 20571-15-7 is a valid CAS Registry Number.
20571-15-7Relevant articles and documents
Denis,Conia
, p. 4593,4595 (1972)
Hepatitis C virus inhibitors
-
, (2008/06/13)
The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.
Hepatitis C virus inhibitors
-
, (2008/06/13)
The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.
